NOTE: Please call us or complete the contact form if you have any questions or wish to apply for Social Security Disability
Due to the severity of liver cancer, nearly all individuals who apply for Social Security Disability (SSD)
will be approved for benefits if you can prove your diagnosis. Liver cancer is the third-most common
type of cancer in the world, killing almost all patients in less than a year. While there is no single
cause attributed to the development of liver cancer, the following factors increase and individuals risk:
- Hepatitis B or C
- Alcohol consumption
- Consumption of Aflatoxin B 1 (found in peanuts, cottonseed meal, corn and other grains)
- Chemical exposure, certain drugs, obesity, diabetes and cirrhosis can all increase your risk of
developing this type of cancer.
Most people who develop liver cancer will not experience any symptoms in the initial stages which
unfortunately allows the disease to spread to other areas of the body before detection. Common
symptoms are unexplained weight loss, loss of appetite, upper abdominal pain, general weakness,
fatigue, upper abdominal pain and nausea to name a few. While surgery is usually indicated along
with chemotherapy only 9-19% live for more that five years after the surgery. In many cases the
treatments involved can be just as debilitating as the condition itself. It is due to this severity that
Compassionate Allowance comes into play when applying for SSD or SSI.
Keep in mind that Social Security is looking at how the disease or treatment prevents you from
working, they will not find you disabled if you can still work with this disease.
Compassionate Allowance fast tracks your claim through the Social Security system. What this
means is that you don’t have to undergo the standard disability claim process which can take years.
Medical records and written statements from treating physicians can all increase your chances of an
approval. Poor documentation and treatment could hinder receiving disability under the
Compassionate Allowance guidelines.